Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended LH Administration (ELHA) in IVF/ICSI
2024-517407-36-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutropin alfa in female infertility, Tubal factor infertility (TFI) and Unexplained infertility (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Change in basal anti-Müllerian hormone (AMH) after 60 days of rhLH pre-treatment. Planned start Nov 2024; status: authorised.
02
Drugs
lutropin alfa
03
Conditions
female infertilityTubal factor infertility (TFI)Unexplained infertility
Beyond the preview
Go deeper on 2024-517407-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517407-36-00.